Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Viridian Therapeutics, Inc. - Common Stock
(NQ:
VRDN
)
13.12
+0.73 (+5.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viridian Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Navigating 6 Analyst Ratings For Viridian Therapeutics
February 28, 2024
Via
Benzinga
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
February 16, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Analyst Ratings for Viridian Therapeutics
December 04, 2023
Via
Benzinga
Where Viridian Therapeutics Stands With Analysts
November 14, 2023
Via
Benzinga
Analyst Ratings for Viridian Therapeutics
September 13, 2023
Via
Benzinga
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
January 18, 2024
Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering.
Via
Benzinga
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
January 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
9 Analysts Have This to Say About Viridian Therapeutics
August 09, 2023
Via
Benzinga
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday
December 18, 2023
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 30 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
December 18, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
November 08, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
November 03, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
October 30, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
October 26, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
October 03, 2023
On Tuesday, 647 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 28, 2023
During Thursday's session, 406 companies made new 52-week lows.
Via
Benzinga
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
September 25, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
September 26, 2023
On Tuesday, 386 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
During the session on Thursday, 461 stocks hit new 52-week lows.
Via
Benzinga
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
September 07, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
August 10, 2023
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on...
Via
Benzinga
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Viridian Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.